Li, Zhilin; Korhonen, Emilia A; Merlini, Arianna; Strauss, Judith; Wihuri, Eleonoora; Nurmi, Harri; Antila, Salli; Paech, Jennifer; Deutsch, Urban; Engelhardt, Britta; Chintharlapalli, Sudhakar; Koh, Gou Young; Flügel, Alexander; Alitalo, Kari (2020). Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. The journal of clinical investigation, 130(4), pp. 1977-1990. American Society for Clinical Investigation 10.1172/JCI130308
Text
130308.2-20201218131647-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (13MB) |
Angiopoietin-2 (Ang2), a ligand of the endothelial Tie2 tyrosine kinase, is involved in vascular inflammation and leakage in critically ill patients. However, the role of Ang2 in demyelinating central nervous system (CNS) autoimmune diseases is unknown. Here, we report that Ang2 is critically involved in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), a rodent model of multiple sclerosis. Ang2 expression was induced in CNS autoimmunity, and transgenic mice overexpressing Ang2 specifically in endothelial cells (ECs) developed a significantly more severe EAE. In contrast, treatment with Ang2-blocking Abs ameliorated neuroinflammation and decreased spinal cord demyelination and leukocyte infiltration into the CNS. Similarly, Ang2-binding and Tie2-activating Ab attenuated the development of CNS autoimmune disease. Ang2 blockade inhibited expression of EC adhesion molecules, improved blood-brain barrier integrity, and decreased expression of genes involved in antigen presentation and proinflammatory responses of microglia and macrophages, which was accompanied by inhibition of α5β1 integrin activation in microglia. Taken together, our data suggest that Ang2 provides a target for increasing Tie2 activation in ECs and inhibiting proinflammatory polarization of CNS myeloid cells via α5β1 integrin in neuroinflammation. Thus, Ang2 targeting may serve as a therapeutic option for the treatment of CNS autoimmune disease.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Theodor Kocher Institute |
UniBE Contributor: |
Deutsch, Urban, Engelhardt, Britta |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1558-8238 |
Publisher: |
American Society for Clinical Investigation |
Language: |
English |
Submitter: |
Ursula Zingg-Zünd |
Date Deposited: |
27 Jan 2021 15:38 |
Last Modified: |
05 Dec 2022 15:44 |
Publisher DOI: |
10.1172/JCI130308 |
PubMed ID: |
32149735 |
Uncontrolled Keywords: |
Autoimmunity Neurological disorders |
BORIS DOI: |
10.48350/150831 |
URI: |
https://boris.unibe.ch/id/eprint/150831 |